Four or more dosage of HCQ showed significant decline of COV
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Healthcare workers (HCWs) are at an elevated risk of contracting COVID-19. While intense occupational exposure associated with aerosol-generating procedures underlines the necessity of using personal protective equipment (PPE) by HCWs, high-transmission efficiency of the causative agent SARS-CoV-2 could also lead to infections beyond such settings. Hydroxychloroquine (HCQ), a repurposed antimalarial drug, was empirically recommended as prophylaxis by the National COVID-19 Task Force in India to cover such added risk.

The current investigation was carried out to identify the factors associated with SARS-CoV-2 infection among HCWs in the country.

-- A case-control design was adopted and participants were randomly drawn from the countrywide COVID-19 testing data portal maintained by the ICMR.
-- The test results and contact details of HCWs, diagnosed as positive (cases) or negative (controls) for SARS-CoV-2 using real-time reverse transcription-polymerase chain reaction (qRT-PCR), were available from this database.
-- A 20-item brief-questionnaire elicited information on place of work, procedures conducted and use of PPE.

Results:
-- Compared to controls, cases were slightly older and had more males.
-- In multivariate analyses, HCWs performing endotracheal intubation had higher odds of being SARS-CoV-2 infected.
-- Consumption of four or more maintenance doses of HCQ was associated with a significant decline in the odds of getting infected; a dose-response relationship existed between frequency of exposure to HCQ and such reductions.
-- In addition, the use of PPE was independently associated with the reduction in odds of getting infected with SARS-CoV-2.

Conclusions:
1. Until results of clinical trials for HCQ prophylaxis become available, this study provides actionable information for policymakers to protect HCWs at the forefront of COVID-19 response.
2. The public health message of sustained intake of HCQ prophylaxis as well as appropriate PPE use need to be considered in conjunction with risk homoeostasis operating at individual levels.

Source: http://www.ijmr.org.in/preprintarticle.asp?id=285520
B●●●●●r A●●●●●●●n and 30 others like this33 shares
Like
Comment
Share
Dr. S●●●●●m S●●●●y P●●●●●l
Dr. S●●●●●m S●●●●y P●●●●●l General Medicine
So,one more study which says HCQ should be taken. Interesting read. But for how long?
Jun 3, 2020Like2
Dr. Ch h●●●●h y●●●v M●●●●●●●●●a
Dr. Ch h●●●●h y●●●v M●●●●●●●●●a General Medicine
Till the pandemic is controlled?
Jun 10, 2020Like